Gutiérrez S, Carbonell E, Galofré P, Creus A, Marcos R
Departament de Genètica i de Microbiologia, Edifici Cn, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Mutat Res. 1997 Jan 3;373(1):39-45. doi: 10.1016/s0027-5107(96)00185-6.
To evaluate the eventual genetic damage induced by therapeutic exposure to 131I, we have studied the presence of micronuclei (MN) in binucleated peripheral blood lymphocytes from a group of 28 hyperthyroidism patients who received 131I sodium iodide, via oral administration. The study was conducted over time and blood samples were obtained before the treatment, and 1 week, 1 month and 3 months after it. The results obtained indicate a positive relationship between dose and BNMN frequency as calculated by the linear regression coefficient, showing significant increases in the frequency of MN and BNMN (binucleated cells with MN) in the subgroup of patients that received more than 500 MBq. Taking into account that the patients studied were treated with relatively low doses of 131I, our positive results support the view that the MN assay is sensitive enough to monitor the chromosome damage resulting from the exposure.
为了评估治疗性暴露于131I所导致的潜在遗传损伤,我们研究了一组28例接受口服碘化钠131I治疗的甲状腺功能亢进患者外周血双核淋巴细胞中微核(MN)的存在情况。该研究随时间进行,在治疗前、治疗后1周、1个月和3个月采集血样。通过线性回归系数计算得出的结果表明,剂量与双核微核(BNMN)频率之间呈正相关,在接受超过500MBq的患者亚组中,微核(MN)和双核微核(BNMN,即含有微核的双核细胞)的频率显著增加。考虑到所研究的患者接受的是相对低剂量的131I治疗,我们的阳性结果支持这样一种观点,即微核试验足够灵敏,能够监测暴露所导致的染色体损伤。